Dynavax Technologies Corp (DVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
58
About the Report
About the Report
Summary
Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company's only marketed product Heplisav-B is an adult vaccine for hepatitis B. Its pipeline includes AZD1419, a drug for the treatment of asthma; DV281, an agonist which focuses on lung tumors and lung metastases; and SD-101, an agonist focusing on immune response to various cancers. Dynavax's pre-clinical pipeline encompasses DV230F for liver tumors, DV1001 for multiple malignancies. The company develops immunotherapies based on toll-like receptor technology for the treatment and prevention of infectious and inflammatory diseases and cancer. It has subsidiary in Germany. Dynavax is headquartered in Berkeley, California, the US.
Dynavax Technologies Corp (DVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Dynavax Technologies Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Dynavax Raises USD40 Million from Hercules Technology 12
Double Helix Raises USD0.048 Million in Seed Financing 13
Partnerships 14
Dynavax Technologies and Quantum Leap Healthcare Collaborative Enter into Agreement 14
Vectura Enters into Agreement with Dynavax Technologies 15
Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 16
Equity Offering 17
Dynavax Technologies Plans to Raise USD150 Million in Public Offering of Shares 17
Dynavax Technologies Raises USD86.2 Million in Public Offering of Shares 18
Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 20
Dynavax Technologies Completes Public Offering Of Shares For USD 85.5 Million 22
Dynavax Technologies Completes Public Offering Of Preferred Stock For USD 46.7 Million 23
Dynavax Technologies Announces Public Offering Of Shares For USD 50 Million 24
Dynavax Technologies Completes Public Offering Of Common Stock For USD 74 Million 25
Debt Offering 26
Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 26
Acquisition 27
McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For USD 78 Million 27
Dynavax Technologies Corp-Key Competitors 28
Dynavax Technologies Corp-Key Employees 29
Dynavax Technologies Corp-Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 05, 2018: Dynavax reports third quarter 2018 financial results, progress on HEPLISAV-B launch, and updated SD-101 data in three patient populations 31
Aug 06, 2018: Dynavax reports second quarter 2018 financial results 33
May 08, 2018: Dynavax Announces First Quarter 2018 Financial Results 34
Mar 08, 2018: Dynavax Reports Fourth Quarter and Year End 2017 Financial Results 35
Nov 03, 2017: Dynavax Reports Third Quarter 2017 Financial Results 36
Aug 02, 2017: Dynavax Reports Second Quarter 2017 Financial Results 37
May 08, 2017: Dynavax Reports First Quarter 2017 Financial Results 38
Mar 13, 2017: Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update 39
Corporate Communications 41
Jun 28, 2018: Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs 41
Mar 02, 2018: Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies 43
Product News 44
06/02/2017: Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy 44
05/19/2017: Dynavax to Present Data on SD-101 in Combination with KEYTRUDA at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 45
05/16/2018: Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting 46
04/17/2018: Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting 47
04/16/2018: Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck 48
03/20/2017: Dynavax to Present Data on SD-101 at the 2017 American Association for Cancer Research Annual Meeting 50
03/20/2017: Dynavax to Present Data on TLR9-Adjuvanted Nanoparticle Cancer Vaccine at the 2017 American Association for Cancer Research Annual Meeting 51
03/20/2017: Dynavax to Present DV-281 at the 2017 American Association for Cancer Research Annual Meeting 52
03/15/2018: Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA for Presentation at the 2018 American Association for Cancer Research Annual Meeting 53
03/06/2017: Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies 54
01/05/2017: Dynavax Provides Update on SD-101 Oncology Program 55
Clinical Trials 56
Oct 19, 2017: Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy 56
Jan 05, 2017: Dynavax Provides Update on DV-281 Oncology Program 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List of Figure
List of Figures
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dynavax Raises USD40 Million from Hercules Technology 12
Double Helix Raises USD0.048 Million in Seed Financing 13
Dynavax Technologies and Quantum Leap Healthcare Collaborative Enter into Agreement 14
Vectura Enters into Agreement with Dynavax Technologies 15
Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 16
Dynavax Technologies Plans to Raise USD150 Million in Public Offering of Shares 17
Dynavax Technologies Raises USD86.2 Million in Public Offering of Shares 18
Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 20
Dynavax Technologies Completes Public Offering Of Shares For USD 85.5 Million 22
Dynavax Technologies Completes Public Offering Of Preferred Stock For USD 46.7 Million 23
Dynavax Technologies Announces Public Offering Of Shares For USD 50 Million 24
Dynavax Technologies Completes Public Offering Of Common Stock For USD 74 Million 25
Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 26
McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For USD 78 Million 27
Dynavax Technologies Corp, Key Competitors 28
Dynavax Technologies Corp, Key Employees 29
Dynavax Technologies Corp, Subsidiaries 30
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.